Patient Condition
HFrEF (ischemic cardiomyopathy), LVEF 32%, NYHA class II-III. A clinical trial of cardiac stem cells (CSC) infusion was enrolled to evaluate the repair effect of stem cells on ischemic heart failure.
Treatment Timeline
| Phase | Details | Date |
|---|
| Clinical trial screening | | |
| CSC cultivation and transfusion | | |
| postoperative monitoring | | |
| follow-up assessments | | |
Treatment Outcome
| before | LVEF 32%, NYHA class II-III, no viable myocardium in the infarct area, VO2 max 15 mL/kg/min |
|---|
| after | LVEF 44%, NYHA class II, improved myocardial perfusion in the infarct margin area, VO2 max 20 mL/kg/min |
|---|
| highlight | LVEF increased by 12% after coronary infusion of autologous cardiac stem cells and improved perfusion in the infarct area |
|---|